TIDMPURI
RNS Number : 3440Z
PuriCore Plc
06 March 2013
PuriCore plc
("PuriCore" or the "Company")
6 March 2013
PuriCore Partners with Onset Dermatologics
Vashe-Based Hydrogel Product for Itch Related to Atopic
Dermatitis to Launch in April
PuriCore (LSE: PURI), the water-based clean technology company,
today announces a marketing partnership agreement with Onset
Dermatologics, a leader in the development and commercialization of
prescription dermatology products. PuriCore will develop and
manufacture a hydrogel dermatologic product for itch symptoms
related to atopic dermatitis (eczema). The product will utilise
PuriCore's patented Vashe(R) Wound Therapy technology. Onset
Dermatologics will market and distribute this new Vashe-based
formulation as Aurstat(R) Anti-Itch Hydrogel and as a component of
Aurstat Kit, exclusively in the US beginning April 2013.
In February, PuriCore announced receipt of a 510(k) regulatory
clearance from the US Food and Drug Administration (FDA) for Vashe
Skin and Wound Hydrogel. Under the terms of the agreement, this
clearance triggers a milestone payment from Onset Dermatologics.
The agreement also includes upfront payments and double-digit
royalty payments on future sales of Aurstat Anti-Inch Hydrogel and
Austat Kit. All intellectual property related to this dermatologic
product remains under the ownership of PuriCore.
Atopic dermatitis is a common chronically relapsing skin
disorder characterized by red, inflamed, dry, cracked itching skin.
According to market research by Global Business Intelligence, the
global atopic dermatitis therapeutics market is valued at greater
than $900 million in annual sales. The US remains the largest
market for atopic dermatitis therapeutics, currently valued at
greater than $400 million. About 6% of the population suffers from
atopic dermatitis within seven primary geographies, the US, the UK,
Germany, France, Spain, Italy, and Japan. Approximately 25 million
patients in these geographies seek treatment from healthcare
practitioners each year.
Michael Ashton, Executive Chairman of PuriCore, said:
"Our Vashe technology provides a strong platform for the further
development and commercialisation in a variety of health sciences
segments. We are confident in our ability to deliver a highly
effective hydrogel to manage the itch caused by atopic dermatitis
and other dermatoses, and we are equally confident of Onset's
capability and expertise to successfully market and continue to
grow sales of this innovative treatment."
Robert J. Moccia, President of Onset Dermatologics, said:
"This partnership with PuriCore allows us to continue to deliver
products that address the needs of millions of patients suffering
atopic dermatitis. By addressing their chief complaint of itch,
Aurstat has become well-established in the marketplace. PuriCore's
new hydrogel formulation allows us to meet the needs of our
customers by offering Aurstat Anti-Itch Hydrogel alone and as part
of Aurstat Kit with HylatopicPlus(R) Cream for convenience to
patients and practitioners."
About PuriCore
PuriCore plc (LSE: PURI) is a water-based clean technology
company focused on developing and commercialising proprietary
solutions that protect people from the spread of infectious
pathogens without causing harm to human health or the environment.
The Company's products are used in a broad range of markets that
depend upon effective pathogen control. PuriCore is the leading
full provider of all products and services required for a safe,
efficient, and compliant endoscope decontamination to protect
patients in UK hospitals. The Company's products are the standard
for food safety and are used for floral care in leading US
supermarket chains. PuriCore also offers a breakthrough wound
therapy solution to treat chronic and acute wounds including
diabetic ulcers and burns. PuriCore is headquartered in Malvern,
Pennsylvania, with operations in Stafford and Clevedon, UK. To
receive additional information on PuriCore, visit www.puricore.com,
which does not form part of this announcement.
About Onset Dermatologics
Headquartered in New York and Cumberland RI, Onset
Dermatologics, a subsidiary of PreCision Dermatology, is a
fully-integrated prescription dermatology company with a mission to
deliver innovative therapies to dermatologists and their patients.
In addition to Aurstat and HylatopicPlus, Onset Dermatologics
markets the prescription brands Locoid(R) , Tretin-X(R) ,
Minocin(R) , and Clarifoam(R) EF to dermatologists and their allied
healthcare providers. Onset is expanding rapidly through internally
generated innovation, acquisitions, in-licensing, and co- marketing
opportunities. For additional information, visit
www.onsetdermatologics.com.
Important Safety Information for Aurstat Anti-Itch Hydrogel
Aurstat Anti-Itch Hydrogel is indicated to manage and relieve
the burning, itching, and pain experienced with various types of
dermatoses, including atopic dermatitis, allergic contact
dermatitis, and radiation dermatitis.
The pH-neutral hydrogel also helps to relieve dry, waxy skin by
maintaining a moist wound and skin environment, which is beneficial
to the healing process. Aurstat Anti-Itch Hydrogel may be used to
relieve the pain of first and second degree burns.
Vashe is a registered trademark of PuriCore, Inc. Aurstat,
HylatopicPlus, Tretin-X, Minocin, and Clarifoam are registered
trademarks of Onset Dermatologics, LLC. Locoid is a registered
trademark of Astellas Pharma Europe B.V. licensed to Onset
Dermatologics, LLC.
Enquiries:
UK US
FTI Consulting Sage Strategic Marketing
Susan Stuart/Simon Jennifer Guinan
Conway
Victoria Foster Mitchell +1 610.410.8111
+44 (0) 20 7831 3113
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions shareholders and prospective shareholders not
to place undue reliance on these forward-looking statements, which
reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRLIFFRVAIRIIV
Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024